TBI diagnostic and therapeutics

1. Definition and Types: TBI is an injury to the brain caused by external force, resulting in a range of effects. It can be classified as mild (concussions), moderate, or severe based on symptoms and impact.
2. Causes: Common causes include falls, vehicle accidents, sports injuries, and violence.
3. Symptoms: Symptoms can vary widely and may include headaches, confusion, memory issues, mood changes, and loss of consciousness.
4. Diagnosis: Diagnosis often involves physical exams, imaging tests like CT or MRI scans, and neuropsychological assessments to evaluate cognitive function.
5. Treatment: Treatment approaches may involve rest, rehabilitation therapies (physical, occupational, speech), medication for symptoms, and in severe cases, surgery.
6. Long-term Effects: Some individuals may experience lasting cognitive, physical, and emotional challenges, requiring ongoing support and management.
7. Prevention: Strategies for preventing TBI include wearing helmets, using seatbelts, and fall-proofing homes, especially for vulnerable populations like the elderly.

The lecture will emphasize the importance of early intervention and a multidisciplinary approach to care.
Traumatic brain injury (TBI) remains a leading global cause of disability, and new data highlight a shift toward precision neurotrauma. In 2024–2025, rapid blood biomarker tests (GFAP, UCH-L1) gained FDA clearance in whole-blood and automated formats, enabling point-of-care triage and safe CT reduction for mild TBI. In the ICU, hypertonic saline is increasingly favored over mannitol for intracranial pressure crises, while the NIH BOOST-3 trial is testing whether combining ICP with brain oxygen monitoring improves outcomes. Single-cell brain atlases and large consortia studies (CENTER-TBI, TRACK-TBI) are mapping the biological and psychosocial heterogeneity of injury, laying the groundwork for personalized treatment. Together, these updates mark a turning point: from generic protocols to tailored, biomarker-driven and multimodal strategies that aim to improve survival and long-term recovery.

For mild traumatic brain injury (mTBI), 2024–2025 updates emphasize earlier, more precise diagnosis and tailored follow-up. Blood biomarkers GFAP and UCH-L1 have now been validated and FDA-cleared in whole-blood, point-of-care formats and automated lab platforms, allowing emergency teams to safely rule out CT-detectable injury within minutes and reduce unnecessary imaging. Studies show GFAP rises within 30 minutes of injury, making ultra-early triage feasible. Large cohort data (CENTER-TBI, TRACK-TBI) highlight how outcomes vary by biological and psychosocial factors, including genetic vulnerability to persistent post-concussion symptoms and mental health challenges, supporting a move toward risk-stratified follow-up. The field is moving from a “rest and discharge” model toward precision mTBI care, where biomarker-guided triage, individualized monitoring, and targeted rehab interventions aim to prevent chronic symptoms and improve recovery trajectories.